Search

Your search keyword '"Folic Acid Antagonists chemistry"' showing total 557 results

Search Constraints

Start Over You searched for: Descriptor "Folic Acid Antagonists chemistry" Remove constraint Descriptor: "Folic Acid Antagonists chemistry"
557 results on '"Folic Acid Antagonists chemistry"'

Search Results

251. Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate.

252. Stereoselective transport of amethopterin enantiomers by the proton-coupled folate transporter.

253. 2D depiction of fragment hierarchies.

254. In vitro biological evaluation of biguanides and dihydrotriazines against Brugia malayi and folate reversal studies.

255. Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition.

256. Binding of natural and synthetic polyphenols to human dihydrofolate reductase.

257. Scoring ensembles of docked protein:ligand interactions for virtual lead optimization.

258. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.

259. Antimalarial drug development: past to present scenario.

260. In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs.

261. Antiproliferative activity against MCF-7 breast cancer cells by diamino-triazaspirodiene antifolates.

262. Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.

263. The Z isomer of 2,4-diaminofuro[2,3-d]pyrimidine antifolate promotes unusual crystal packing in a human dihydrofolate reductase ternary complex.

264. In vitro biological activity and structural analysis of 2,4-diamino-5-(2'-arylpropargyl)pyrimidine inhibitors of Candida albicans.

265. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.

267. Carborane clusters in computational drug design: a comparative docking evaluation using AutoDock, FlexX, Glide, and Surflex.

268. Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.

269. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.

270. Ligand-receptor communication and drug design.

271. Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs.

272. Towards new antifolates targeting eukaryotic opportunistic infections.

273. Interactions between cycloguanil derivatives and wild type and resistance-associated mutant Plasmodium falciparum dihydrofolate reductases.

274. A novel in silico approach to drug discovery via computational intelligence.

275. Communication breakdown: protein dynamics and drug design.

276. Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: modulation of dynamics within a structural state.

277. Mutational 'hot-spots' in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: sequence and structural comparison.

278. Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drug-resistant falciparum malaria.

279. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.

280. Screening of DHFR-binding drugs by MALDI-TOFMS.

281. On the interpretation and interpretability of quantitative structure-activity relationship models.

282. Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from cryptosporidium.

283. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints.

284. Identification of an anti-MRSA dihydrofolate reductase inhibitor from a diversity-oriented synthesis.

285. Studies on development of insoluble drugs as pharmaceutical suspensions by response surface methodology.

286. Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.

287. Structure-guided development of efficacious antifungal agents targeting Candida glabrata dihydrofolate reductase.

288. Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine.

289. Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.

290. The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.

291. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.

292. A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor.

293. Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate.

294. Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition.

295. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.

296. QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives.

297. In vitro effects of Plasmodium falciparum dihydrofolate reductase inhibitors on normal and cancer cell proliferation.

298. Characterization and comparative studies of zebrafish and human recombinant dihydrofolate reductases--inhibition by folic acid and polyphenols.

299. A balancing act between net uptake of water during dihydrofolate binding and net release of water upon NADPH binding in R67 dihydrofolate reductase.

300. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.

Catalog

Books, media, physical & digital resources